Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

Abstract Background By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan...

Full description

Bibliographic Details
Main Authors: Joshua K. Kays, Safi Shahda, Melissa Stanley, Teresa M. Bell, Bert H. O'Neill, Marc D. Kohli, Marion E. Couch, Leonidas G. Koniaris, Teresa A. Zimmers
Format: Article
Language:English
Published: Wiley 2018-08-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Cachexia
Pancreatic cancer
Sarcopenia
FOLFIRINOX
Muscle wasting
Online Access:https://doi.org/10.1002/jcsm.12307

Similar Items

Similar Items